



## DEVELOPMENT OF VASCULARIZED TUMOR-ON-CHIPS

Toward a physiological microsystem modeling  
the glioblastoma and blood-brain barrier.



Agathe Figarol, Forum du Cancéropôle Est, 10/11/2023

Université de Franche-Comté, CNRS, FEMTO-ST, F-25000 Besançon, France


Département MN2S : Micro Nano Sciences et Systèmes

Equipe BIND : BiolInterfaces aNd Design

[agathe.figarol@femto-st.fr](mailto:agathe.figarol@femto-st.fr)



**13<sup>e</sup> FORUM 2023**  
**CANCÉROPÔLE Est**




# CONTEXT




The valley of death of pharmaceutical drug development  
≈ 90% transition failure from bench to bed

Conventional preclinical models lack pertinence

- Poor clinical projections in patients
- Time and money consuming



# CONTEXT




## Drug development

- For mental and neurologic diseases
- Have twice the risk of failure

The **BBB** : blood brain barrier blocks the transport of

- 100% of large pharmaceutical drugs
- 98% of small pharmaceutical drugs



# CONTEXT

The **GBM** : glioblastoma multiforme

- the most frequent, and
- the most aggressive brain cancer


1% of all cancers → 2% of cancer-linked mortality

- surgery + radiotherapy + chemotherapy (TMZ)
- 12 to 18 months of life expectancy

Lot of expectations on nanocarriers


- Could facilitate the transport through the BBB
- Can reduce the drug toxicity

But < 1% nanodrugs reach the tumor & the transition to clinic is still a challenge.



*MRI scan of a GBM in a 15 year old*

# PRECLINICAL BBB AND GBM MODELS



# A GLOBAL PROBLEMATIC

## ↗ neurologic pathologies


- + 17,3% of brain and central nervous system cancers (1990-2016)
- 7,7 millions DALYS (disability-adjusted life years)

## 10 millions animals / year in EU

- Directive 2010/63/EU
- 3Rs

## High industrial expectations

- Microfabrication allowed organ-on-chips development
- Pharmaceutical pharmacy are waiting for efficient alternatives



# THE SIBorG PROJECT & METHODOLOGY

Goals: ↗ clinical transfer rate  
↗ innovative therapies against brain cancer

Objective: a new preclinical model to screen drug candidates for transport and therapeutic efficiency



- I. Optimization of a **hydrogel for 3D BBB vascularization** modelling
- II. Development of a **vascularized GBM tumor-on-chip**

# I. OPTIMIZATION OF A HYDROGEL FOR 3D BBB VASCULARIZATION MODELLING

*Post-doctorate in Osaka University*

# 3D CULTURE IN A HYDROGEL

Osaka University, Chemical engineering department, Matsusaki's laboratory



Hydrogel : collagène de type I, fibrine



Cellules endothéliales




Péricytes



Astrocytes



Collagen (17 mg/mL)  
+ fibrinogen (6,7 mg/mL)  
+ medium

Cells ( $5,8 \cdot 10^6$   $\text{cells}/\text{mL}$ )  
+ thrombin (10 U/mL)  
+ medium



# 3D CULTURE IN A HYDROGEL

Osaka University, Chemical engineering department, Matsusaki's laboratory



Hydrogel : collagène de type I, fibrine



Cellules endothéliales




Péricytes



Astrocytes

7 days later


Incubation at 37°C, 5% CO<sub>2</sub> with medium change at d3





Self-organization in a 3D network of brain microvasculature

# Validation of the BBB vascularization

- Collagen and fibrin fibrous gel (SEM)









- Capillary lumen (immunohistochemistry CD31 for tight junctions of endothelial cells)







# Validation of the BBB vascularization

- Capillary network (immunofluorescence **CD31** for endothelial cells, cell tracker for pericytes, **cell tracker** for astrocytes, **Dapi** for nuclei)




# Validation of the BBB vascularization




- Protein and gene expression (immunofluorescence, Western blot, PCR, transcriptomic)



# Direct possible applications in toxicology



## First assays under medium flow



## II. DEVELOPMENT OF A VASCULARIZED GBM TUMOR-ON-CHIP

*Work in progress*



Sylvain Chamouton  
Project ISIFC 2022



Marion Pouit  
Intern ISIFC 2023



Roumaïssa Mosbah  
Intern M2 2023




Léo Durand  
Project ISIFC 2023





Maxime Gourgues  
PhD student 2023-2026

# MICROCHIP DESIGN



## 4<sup>th</sup> prototypes:


- Mold obtained by CAD and PLA (polylactic acid) 3D printing
- PDMS (polydimethylsiloxane) cast and polymerized
  - Common because cheap, easy to handle, permeable to gaz
  - + or – optically transparent
  - Planned functionalization to avoid drug adsorption






# CENTRAL CHANNEL

Veinule as a central channel

- Carved with an acupuncture needle
- Perfused with medium to mimic blood flow







- Prototypes of the device needed to guide the needle
  - The diameter of the veinule in the hydrogel is stable
  - Complexification of the veinule trajectory
- Impact of the veinule design on angiogenesis



# CELL COCULTURE

- Reproduction of the vasculature self-organization conditions
- Optimization of the collagen-fibrin hydrogel
- Endothelial cell seeding in the central veinule





- Optimization of the coculture with U87-MG glioblastoma cell line  
→ Study of the 3D organization, and angiogenesis in a tumoral environment


# FLOW

- First assays in acellular condition
- Optimization of the chip design
- Optimization of the flow parameters
  - speed, volume, duration
  - pump type and controllers

→ Impact on the tissues and cell phenotypes




Open chip




Close chip  
in PDMS

# BIOSENSORS



- Transport biosensor by acoustic waves
- Controlled microporous membrane for cell culture
- Other physical sensors (pH, T, O<sub>2</sub>)



Muhammad Hamidullah

Postdoctoral MSCA SmooC

# COLLABORATIONS

**Osaka University**

Chemical engineering department

**Toppan Joint venture**



**Tokyo University of Pharmacy  
and Life Science**



**PÉPITE UR 4267**  
**UTINAM UMR 6213**  
**Université de Franche-Comté**



**BaRITOOn UMR 1053**  
**Université de Bordeaux**



Michiya MATSUSAKI	BBB model, extracellular matrix
Asuka YAMADA	Collagen microfiber sponge
Tomomi FURIHATA	BBB cell lines

Arnaud BEDUNEAU	Nanocarriers against glioblastoma
Stéphane ROUX	

Océane MARTIN	Microbiology, oncology Gut-Brain axis
---------------	--

# LOCAL TEAM



## FUNDINGS

RÉGION  
BOURGOGNE  
FRANCHE  
COMTE



fondation  
DESCROIX-VERNIER



UNIVERSITÉ DE  
FRANCHE-COMTÉ

Membre de

UBFC  
UNIVERSITÉ  
BOURGOGNE FRANCHE-COMTÉ


école doctorale sciences pour l'ingénieur et microtechniques

SPIM

anr<sup>®</sup>  
agence nationale  
de la recherche  
AU SERVICE DE LA SCIENCE



Agathe FIGAROL	Nano-bio-interaction, tissue engineering
Thérèse LEBLOIS	Biomicrodevices and biosensors
Vincent HUMBLOT	Biointerfaces, chemical functionalization
Franck CHOLLET	Microfabrication, electroacoustic
Muhammad HAMIDULLAH	Microsystems, biosensors
Bruno WACOGNE	Optical sensors
Maxime GOURGUES	PhD student, GBM-sur-puce
<i>Upcoming</i>	<i>M2 intern</i>
<i>Upcoming</i>	<i>PhD student</i>
Céline ELIE-CAILLE	Microvesicles, exosome



# THANK YOU FOR YOUR ATTENTION